CRISPR Therapeutics Reports $100M Casgevy Sales, 300+ Patient Starts and 80% ANGPTL3 Edit
Patient initiations at CRISPR Therapeutics tripled to over 300 in 2025, with full-year Casgevy sales above $100 million. Early CTX310 in vivo data showed an 80% ANGPTL3 edit drive yielding 50% LDL and 60% triglyceride reductions.
1. Patient Growth and Casgevy Sales
Patient initiations rose from about 100 in 2024 to over 300 in 2025, driving Casgevy full-year sales beyond $100 million. Cell collections are beginning to inflect with a projected geometric growth pattern as more treatment sites become productive.
2. CTX310 In Vivo Cardiovascular Data
Early CTX310 in vivo data targeting ANGPTL3 achieved an 80% gene edit in hepatocytes, resulting in roughly 50% LDL cholesterol and 60% triglyceride reductions. The company is engaging regulators to define the registrational trial path across hypertriglyceridemia, mixed dyslipidemia and familial hypercholesterolemia subpopulations.
3. Autoimmune and Lp(a) Program Update
In its autoimmune portfolio, CRISPR Therapeutics completed CTX320 dose escalation with up to a 73% Lp(a) reduction and is evaluating CTX321’s near-2x greater editing potency. Progress on Phase II advancement will align with external HORIZON outcomes data to guide potency and timing decisions.
4. Pipeline Expansion and Future Milestones
By mid-2027, CRISPR Therapeutics expects data from six programs beyond Casgevy across multiple indications, including CTX340 for refractory hypertension and SyNTase-driven alpha-1 antitrypsin deficiency. Ongoing investments in gentler conditioning agents and in vivo HSC delivery aim to broaden market access and enhance the in vivo platform.